Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.58 |
| ▸ | DRD4 | P21917 | 1/20 | 0.58 |
| ▸ | DRD3 | P35462 | 1/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | CRHBP | P24387 | 1/20 | 0.51 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4937120 | 0.95 | HRH3 (0.57) | DRD2DRD4DRD3HRH3KCNH2 | |
| SCHEMBL4743102 | 0.93 | HRH3 (0.60) | DRD2DRD4DRD3HRH3KCNH2 | |
| SCHEMBL28180989 | 0.93 | HRH3 (0.60) | DRD2DRD4DRD3HRH3KCNH2 | |
| SCHEMBL28180977 | 0.93 | HRH3 (0.60) | DRD2DRD4DRD3HRH3KCNH2 | |
| SCHEMBL17971426 | 0.93 | HRH3 (0.60) | DRD2DRD4DRD3HRH3KCNH2 | |
| SCHEMBL28180194 | 0.93 | HRH3 (0.60) | DRD2DRD4DRD3HRH3KCNH2 | |
| SCHEMBL28180976 | 0.93 | HRH3 (0.60) | DRD2DRD4DRD3HRH3KCNH2 | |
| SCHEMBL378659 | 0.91 | KCNH2 (0.55) | DRD2DRD4DRD3HRH3KCNH2 | |
| SCHEMBL2480658 | 0.91 | KCNH2 (0.55) | DRD2DRD4DRD3HRH3KCNH2 | |
| SCHEMBL10737114 | 0.89 | LSS (0.57) | DRD2DRD4DRD3KCNH2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160002220-A1 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2016-01-07 | — | — | US | claimed |
| US-20070185155-A1 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | claimed |
| US-20250270193-A1 | ARYLIMIDAMIDES FOR USE IN TREATMENT OF CANCERS | OHIO STATE INNOVATION FOUNDATION | 2025-08-28 | — | — | US | disclosed |
| US-12172980-B2 | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | XWPharma Ltd. (KY) | 2024-12-24 | — | — | US | disclosed |
| EP-3856719-B1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | XWPHARMA LTD (KY) | 2023-06-07 | — | — | EP | disclosed |
| WO-2023069613-A1 | ARYLIMIDAMIDES FOR USE IN TREATMENT OF CANCERS | OHIO STATE INNOVATION FOUNDATION (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20220380339-A1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | XWPharma Ltd. (KY) | 2022-12-01 | — | — | US | disclosed |
| US-11420955-B2 | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | XWPharma Ltd. (KY) | 2022-08-23 | — | — | US | disclosed |
| CN-114042070-A | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2022-02-15 | — | — | CN | disclosed |
| CN-112004802-B | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2021-12-28 | — | — | CN | disclosed |
| EP-3331864-B1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2021-11-03 | — | — | EP | disclosed |
| US-5093353-A | 2,2-di-substituted benzopyran leukotriene-D4 antagonists | G. D. SEARLE & CO. (US) | 1992-03-03 | — | — | US | disclosed |
| US-5079248-A | Antifibrillatory agents; side effect reduction | PFIZER INC. (US) | 1992-01-07 | — | — | US | disclosed |
| US-4959366-A | Anti-arrhythmic agents | PFIZER INC. (US) | 1990-09-25 | — | — | US | disclosed |
| EP-0342664-A2 | 2,2-disubstituted benzopyran leukotriene-D4 antagonists | G.D. Searle & Co. (US) | 1989-11-23 | — | — | EP | disclosed |
| EP-0046590-B1 | PHEN(ALK)OXY-SUBSTITUTED OXIRANE-CARBOXYLIC ACIDS, PROCESS FOR THEIR PREPARATION, THEIR USE AND DRUGS CONTAINING THEM | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1985-05-22 | — | — | EP | disclosed |
| US-4337267-A | HYPOKETONEMIC, HYPOGLYCEMIC, ANTIDIABETIC | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1982-06-29 | — | — | US | disclosed |
| WO-1982000643-A1 | SUBSTITUTED OXIRANECARBONIC ACIDS,PREPARATION AND PHARMACEUTICAL UTILISATION THEREOF | BYK GULDEN LOMBERG CHEM FAB (DE) | 1982-03-04 | — | — | WO | disclosed |
| EP-0046590-A2 | Phen(alk)oxy-substituted oxirane-carboxylic acids, process for their preparation, their use and drugs containing them | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1982-03-03 | — | — | EP | disclosed |
| US-4258045-A | 2,4-DIAMINO-5-((ARYLALKOXY)BENZYL)-PYRIMIDINES AS ANTIBACTERIAL, ANTIPROTOZOAL AND ANTITUMOR AGENTS | MERCK & CO., INC. (US) | 1981-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270193-A1 | ARYLIMIDAMIDES FOR USE IN TREATMENT OF CANCERS | PAICS, ABL1, BCR | DRD2 4782/4885DRD4 4734/4885DRD3 4797/4885 |
| US-20220380339-A1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | HRH3, HRH4, HRH2 | DRD2 507/4885DRD4 1120/4885DRD3 420/4885 |
| US-20160002220-A1 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | CHRM3, CHRNG, CHRM2 | DRD2 505/4885DRD4 1311/4885DRD3 794/4885 |
| US-12172980-B2 | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | HRH3, HRH4, HRH2 | DRD2 525/4885DRD4 1131/4885DRD3 395/4885 |
| US-11420955-B2 | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | HRH3, HRH4, HRH2 | DRD2 525/4885DRD4 1131/4885DRD3 395/4885 |
| US-20070185155-A1 | Muscarinic acetylcholine receptor antagonists | CHRM3, CHRNG, CHRM2 | DRD2 546/4885DRD4 1517/4885DRD3 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.